| Title | Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter, non-interventional study |
| Authors | Cheng Ying Wang Yan Zhao Jun Liu Yunpeng Gao Hongjun Ma Kewei Zhang Shucai Xin Hua Liu Jiwei Han Chengbo Zhu Zhitu Wang Yan Chen Jun Wen Fugang Li Junling Zhang Jie Zheng Zhendong Dai Zhaoxia Piao Hongmei Li Xiaoling Li Yinyin Zhong Min Ma Rui Zhuang Yongzhi Xu Yuqing Qu Zhuohui Yang Haibo Pan Chunxia Yang Fan Zhang Daxin Li Bing |
| Affiliation | Department of Medical Oncology, Jilin Provincial Cancer Hospital, Changchun, China. Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. Department of Thoracic Oncology, Beijing Cancer Hospital, Beijing, China. Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China. Department of Lung Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China. Department of Respiratory Medicine, The First Hospital of Jilin University, Changchun, China. Department of Oncology, Beijing Chest Hospital, Beijing, China. Department of Thoracic Surgery, China-Japan Union Hospital of Jilin University, Changchun, China. Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China. Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China. Department of Cancer Center, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, China. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China. Department of Oncology, Anshan Cancer Hospital, Anshan, China. Department of Respiratory and Critical Care Medicine, The Second of Hospital of Jilin University, Changchun, China. Department of Oncology, The General Hospital of Shenyang Military, Shenyang, China. Department of Respiratory Medicine, Yanbian University Hospital, Yanbian, China. Department of Medical Oncology, Liaoning Cancer Hospital, Shenyang, China. Department of Oncology, Shenyang Chest Hospital, Shenyang, China. Department of Medical Oncology, Dalian Municipal Central Hospital, Dalian, China. Department of Thoracic, Liaoning Cancer Hospital, Shenyang, China. Department of Oncology, Daqing Oilfield General Hospital, Daqing, China. Medical Department, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. Department of Oncology, Siping Cancer Hospital, Siping, China. Department of Oncology, Jilin Municipal Cancer Hospital, Jilin, China. Department of Medical Oncology, Third People's Hospital of Dalian, Dalian, China. Department of Thoracic Surgery, Peking University People's Hospital, Beijing, China. Department of Oncology, The First Affiliated Hospital of Harbin Medical University, Harbin, China. Department of Medical Oncology, Jilin Center Hospital, Jilin, China. |
| Keywords | Clinical practice,epidermal growth factor receptor,mutation,non-small-cell lung cancer,tyrosine kinase inhibitor |
| Issue Date | 2018 |
| Publisher | Thoracic cancer |
| Citation | Thoracic cancer. 2018. |
| Abstract | Before tyrosine kinase inhibitor (TKI) therapy can be administered in patients with advanced non-small cell lung cancer (NSCLC), EGFR mutation testing is required. However, few studies have evaluated the extent of EGFR testing in real-world practice in China.A multicenter, observational study of EGFR testing in NSCLC patients in North China was conducted. Treatment-naïve patients or those with postoperative recurrent stage IIIB/IV NSCLC were enrolled. The primary objective was EGFR testing rate. Secondary objectives included EGFR mutation status, EGFR testing methods and specimens, factors associated with EGFR testing, and overall survival with or without EGFR testing.Overall, 2809 patients with stage IIIB/IV NSCLC were enrolled; 90.78% had adenocarcinoma. The EGFR screening rate was 42.54%. EGFR testing rates were higher in tumor samples obtained by lymph node puncture, and in patients with urban medical insurance, adenocarcinoma, non-smokers, or those located in developed cities (all P < 0.001). The EGFR mutation rate was 46.44%. The most commonly used specimens for EGFR testing were biopsy tumor samples (67.53%). PCR-based methods (72.05%), Sanger sequencing (5.36%), and Luminex liquid chip (5.10%) were the most frequently used testing platforms. Similar positive EGFR mutation rates were achieved with different platforms. TKI therapy was the first-line treatment administered to most EGFR-positive patients (56.22%), and chemotherapy in EGFR-negative patients (84.88%). Overall survival was higher in EGFR-tested than in untested patients (27.50 vs. 19.73 months; P = 0.007).Real-world EGFR testing rates for NSCLC in North China were relatively low because of clinical and social factors, including medical insurance coverage.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. |
| URI | http://hdl.handle.net/20.500.11897/528665 |
| ISSN | 1759-7714 |
| DOI | 10.1111/1759-7714.12859 |
| Indexed | PubMed |
| Appears in Collections: | 人民医院 |
